There are currently 51 clinical trials in Chula Vista, California looking for participants to engage in research studies. Trials are conducted at various facilities, including Profil Institute for Clinical Research Inc., GSK Investigational Site, GW Research Inc, and eStudySite. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Product Surveillance Registry
NCT01524276
Recruiting
The purpose of the Registry is to provide continuing evaluation and periodic reporting of safety and effectiveness of Medtronic market-released products. The Registry data is intended to benefit and support interests of patients, hospitals, clinicians, regulatory bodies, payers, and industry by streamlining the clinical surveillance process and facilitating leading edge performance assessment via the least burdensome approach.
Gender:
ALL
Ages:
All
Trial Updated:
04/30/2025
Locations: Not set, Chula Vista, California
Conditions: Cardiac Rhythm Disorders, Urological Disorders, Neurological Disorders, Cardiovascular Disorders, Digestive Disorders, Intracranial Aneurysm, Mechanical Circulatory Support, Respiratory Therapy, Aortic, Peripheral Vascular and Venous Disorders, Minimally Invasive Surgical Procedures, Diagnostic Techniques and Procedures, Surgical Procedures, Operative, Renal Insufficiency, Neurovascular, Coronary Artery Disease, Ear, Nose and Throat Disorder
Register for Updates
A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Lower Blood Sugar in People With Type 2 Diabetes
NCT06326047
Recruiting
This study will look at how well a new medicine called NNC0519-0130 helps people with type 2 diabetes lower their blood sugar and body weight. The study will test up to 7 different doses of NNC0519-0130. Which treatment participant will get is decided by chance. Participants will take 1-3 injections once a week. The study medicine will be injected under skin with a thin needle in the stomach, thigh, or upper arm. The study will last for about 40 weeks.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/27/2025
Locations: Velocity Clin Res-Chula Vista, Chula Vista, California
Conditions: Diabetes Mellitus, Type 2
Register for Updates
Life's End Benefits of cannaBidiol and tetrahYdrocannabinol
NCT05644262
Recruiting
This is a multicenter randomized double-blind placebo-controlled Phase 2 study of an oral combination of tetrahydrocannabinol (THC) and cannabidiol (CBD) compared to placebo over 12 weeks. This study is designed to test the hypothesis that treatment with an oral combination of THC/CBD will reduce agitation hospice care-eligible patients with agitation and dementia as measured by the Cohen Mansfield Agitation Inventory (CMAI) when compared to placebo at 2 weeks. This study will enroll approximat... Read More
Gender:
ALL
Ages:
40 years and above
Trial Updated:
04/24/2025
Locations: The Neuron Clinic, Chula Vista, California
Conditions: Agitation, Dementia
Register for Updates
Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)
NCT06098079
Recruiting
A randomized, double-blinded, placebo controlled study intended to capture cardiovascular outcomes during real-world use of naltrexone/bupropion (NB).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/21/2025
Locations: Velocity Clinical Research, Chula Vista, California
Conditions: Obesity
Register for Updates
A Study of RSLV-132 in Females With Sjögren's Syndrome
NCT06440525
Recruiting
The goal of this clinical study is to learn if RSLV-132 improves the symptoms of SS in adults. It will also learn about the safety of RSLV-132. The main questions it aims to answer are: * Does RSLV-132 improve the cardinal symptoms of Sjogren's including fatigue, dryness and pain? * Does RSLV-132 improve the tiredness/fatigue caused by Sjogren's? * What are the blood levels of RSLV-132 over time? * What is the immune (antibody) response in the body to RSLV-132? * What is the safety profile of R... Read More
Gender:
FEMALE
Ages:
Between 18 years and 65 years
Trial Updated:
04/19/2025
Locations: Resolve Clinical Site, Chula Vista, California
Conditions: Primary Sjögren Syndrome
Register for Updates
Efficacy and Safety of Rexlemestrocel-L Combined With HA* in Participants With Moderate to Severe Chronic Low Back Pain
NCT06325566
Recruiting
The primary purpose of this study is to evaluate the efficacy of rexlemestrocel-L+HA compared to control in reducing low back pain at 12 months post-treatment and safety of a single injection of rexlemestrocel-L+HA injected into a lumbar intervertebral disc compared to control through 12 months post-treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/11/2025
Locations: TriWest Research Associates, Chula Vista, California
Conditions: Degenerative Disc Disease
Register for Updates
OPTDR01 Feasibility for Automated Diabetic Retinopathy Detection
NCT06343350
Recruiting
In the United States, only 62% of the 37 million people with diabetes receive annual screening exams for diabetic retinopathy. One of the goals of the US Department of Health and Human Services Healthy People 2030 campaign is to increase diabetic retinopathy screening rates to 70.3%. Research indicates that low screening rates are associated with a variety of factors, including income levels, race and lack of access to care. Furthermore, because diabetic retinopathy frequently presents asymptoma... Read More
Gender:
ALL
Ages:
22 years and above
Trial Updated:
03/24/2025
Locations: Gastro SB, Chula Vista, California
Conditions: Diabetic Retinopathy, Diabetes
Register for Updates
Dose Exploration Study of GSK4532990 in. Participants With NASH or Suspected NASH
NCT06104319
Recruiting
The purpose of this study is to understand how the drug GSK4532990 is processed in the body (pharmacokinetics) and how it works in the liver (pharmacodynamics) as well as to ensure it is safe and well-tolerated. The total study duration for each participant will be approximately 24-36 weeks.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
03/24/2025
Locations: GSK Investigational Site, Chula Vista, California
Conditions: Non-alcoholic Fatty Liver Disease
Register for Updates
Study to Evaluate Efficacy, Safety and Tolerability of HM15211(efocipegtrutide) in Subjects
NCT04505436
Recruiting
This study is a phase 2 study to Evaluate Efficacy, Safety and Tolerability of HM15211 Treatment for 12 Months in Subjects with Biopsy Confirmed NASH
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
03/20/2025
Locations: Precision Research Institute, LLC. (PRI), Chula Vista, California
Conditions: NASH - Nonalcoholic Steatohepatitis
Register for Updates
Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)
NCT05925803
Recruiting
The purpose of this study is to evaluate the efficacy and safety of treatment with subcutaneous anifrolumab versus placebo in adult participants with systemic sclerosis. The target population for this study includes patients who meet the 2013 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) classification for systemic sclerosis, either limited or diffuse cutaneous subsets, with a disease duration of less than 6 years from first non-Raynaud's phenomenon symptom.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
03/04/2025
Locations: Research Site, Chula Vista, California
Conditions: Systemic Sclerosis, Scleroderma
Register for Updates
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)
NCT05147220
Recruiting
To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis (RMS)
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
02/28/2025
Locations: The Neuron Clinic, Chula Vista, California
Conditions: Relapsing Multiple Sclerosis
Register for Updates
Evaluation of the Safety and Tolerability of Gemini in Subjects With Stage 3-4 Chronic Kidney Disease.
NCT06863467
Recruiting
Gemini is being evaluated in a placebo controlled, single dose, escalating dose study to evaluate the safety and tolerability of intravenous Gemini in adult subjects with stage 3 or 4 chronic kidney disease. Pharmacokinetics will be evaluated and measurements of the effect of Gemini on pharmacodynamic activity will be measured to assess changes in potential pharmacodynamic markers.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
02/28/2025
Locations: California Institute of Renal Research, Chula Vista, California
Conditions: Renal Insufficiency, Chronic, Chronic Kidney Disease stage3, Chronic Kidney Disease stage4
Register for Updates